66400-12-2

Basic information

• Product Name: 1,3-DIISOPROPYLPYRIMIDINE-2,4,6(1H,3H,5H)-TRIONE
• Synonyms: 1,3-DIISOPROPYLPYRIMIDINE-2,4,6(1H,3H,5H)-TRIONE
• CAS NO: 66400-12-2
• Molecular Formula: C₁₀H₁₆N₂O₃
• Molecular Weight: 212.25
• Mol File: 66400-12-2.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,3-DIISOPROPYLPYRIMIDINE-2,4,6(1H,3H,5H)-TRIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-DIISOPROPYLPYRIMIDINE-2,4,6(1H,3H,5H)-TRIONE(66400-12-2)
• EPA Substance Registry System: 1,3-DIISOPROPYLPYRIMIDINE-2,4,6(1H,3H,5H)-TRIONE(66400-12-2)

Safety Data

• Hazardous Substances Data: 66400-12-2(Hazardous Substances Data)

Usage

Type of compound

Derivative of barbituric acid

Primary uses

Anticonvulsant and sedative medication

Mechanism of action

Enhances the effects of gamma-aminobutyric acid (GABA) in the brain

Effects

Calming and sedative

Administration methods

Intravenously or intramuscularly

Medical applications

Treatment of seizures and epilepsy

Habit-forming potential

Yes, habit-forming

Supervision

Should only be used under the supervision of a healthcare professional

Upstream product

• 75-31-0 isopropylamine 
• 1663-67-8 malonoyl dichloride 
• 141-82-2 malonic acid 
• 693-13-0 diisopropyl-carbodiimide 

Downstream Products

• 329014-86-0 5-{(4-hydroxy-phenylamine)-methylene}-1,3-diisopropyl-pyrimidine-2,4,6-trione 
• 329014-83-7 5-{(4-propargyloxy-phenylamine)-methylene}-1,3-diisopropyl-pyrimidine-2,4,6-trione 
• 329014-82-6 5-{[4-(2-ethyl-hexyloxy)-phenylamine]-methylene}-1,3-diisopropyl-pyrimidine-2,4,6-trione 
• 329014-87-1 5-{(2,4-dihydroxy-phenylamine)-methylene}-1,3-diisopropyl-pyrimidine-2,4,6-trione 

Relevant articles and documents

C-H Acidity of Barbituric Acids

The C-5-acidity of barbituric acids is correlated with the rates of proton transfer to and from that carbon atom.

Selective Inhibitors of a Human Prolyl Hydroxylase (OGFOD1) Involved in Ribosomal Decoding

Human prolyl hydroxylases are involved in the modification of transcription factors, procollagen, and ribosomal proteins, and are current medicinal chemistry targets. To date, there are few reports on inhibitors selective for the different types of prolyl hydroxylases. We report a structurally informed template-based strategy for the development of inhibitors selective for the human ribosomal prolyl hydroxylase OGFOD1. These inhibitors did not target the other human oxygenases tested, including the structurally similar hypoxia-inducible transcription factor prolyl hydroxylase, PHD2.

Pyrimidine-2,4,6-trione light screening compositions

The present invention provides compounds of formula I, which are effective in absorbing ultraviolet radiation and can be used as sunscreen agents: wherein R1and R2are each independently C2-C18alkyl, C5/sub